-
Corrigendum to “Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment” [Neoplasia, Volume 22, Issue 2 (2020) 111–119] Neoplasia (IF 4.8) Pub Date : 2024-03-15 Steven Kregel, Chao Wang, Xin Han, Lanbo Xiao, Ester Fernandez-Salas, Pushpinder Bawa, Brooke L. McCollum, Kari Wilder-Romans, Ingrid J. Apel, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan
-
PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures Neoplasia (IF 4.8) Pub Date : 2024-03-14 Heidi Rausio, Alejandra Cervera, Vanina D. Heuser, Gun West, Jaana Oikkonen, Elena Pianfetti, Marta Lovino, Elisa Ficarra, Pekka Taimen, Johanna Hynninen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Carpén, Kaisa Huhtinen
Gene fusions are common in high-grade serous ovarian cancer (HGSC). Such genetic lesions may promote tumorigenesis, but the pathogenic mechanisms are currently poorly understood. Here, we investigated the role of a PIK3R1-CCDC178 fusion identified from a patient with advanced HGSC. We show that the fusion induces HGSC cell migration by regulating ERK1/2 and increases resistance to platinum treatment
-
Advancing glioblastoma treatment by targeting metabolism Neoplasia (IF 4.8) Pub Date : 2024-03-12 Jinyi Zhao, Xuemei Ma, Peixian Gao, Xueqi Han, Pengxiang Zhao, Fei Xie, Mengyu Liu
Alterations in cellular metabolism are important hallmarks of glioblastoma(GBM). Metabolic reprogramming is a critical feature as it meets the higher nutritional demand of tumor cells, including proliferation, growth, and survival. Many genes, proteins, and metabolites associated with GBM metabolism reprogramming have been found to be aberrantly expressed, which may provide potential targets for cancer
-
ST6GAL1 is associated with poor response to chemoradiation in rectal cancer Neoplasia (IF 4.8) Pub Date : 2024-03-10 Mary Smithson, Sameer Al Diffalha, Regina K. Irwin, Gregory Williams, M. Chandler McLeod, Vivek Somasundaram, Susan L. Bellis, Karin M. Hardiman
Colorectal cancer is the third most common cause of cancer death. Rectal cancer makes up a third of all colorectal cases. Treatment for locally advanced rectal cancer includes chemoradiation followed by surgery. We have previously identified ST6GAL1 as a cause of resistance to chemoradiation and hypothesized that it would be correlated with poor response in human derived models and human tissues. Five
-
IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis Neoplasia (IF 4.8) Pub Date : 2024-02-28 Bingting Yu, Danny de Vos, Xiaopei Guo, SanFei Peng, Wenjie Xie, Maikel P. Peppelenbosch, Yang Fu, Gwenny M. Fuhler
is a significant risk factor for development of gastric cancer (GC), one of the deadliest malignancies in the world. However, the mechanism by which induces gastric oncogenesis remains unclear. Here, we investigated the function of IL-6 in gastric oncogenesis and macrophage-epithelial cell interactions. We analyzed publicly available datasets to investigate the expression of and infiltration of M2
-
Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations Neoplasia (IF 4.8) Pub Date : 2024-02-27 Jing Hu, Xinyi Chen, Feifei Sun, Lili Liu, Long Liu, Zimeng Yang, Hanwen Zhang, Zeyuan Yu, Ru Zhao, Yueyao Wang, Hui Liu, Xiaorong Yang, Fusheng Sun, Bo Han
While alterations have been established as a driver in various solid malignancies, the characterization of alterations in prostate cancer (PCa) has not been thoroughly interrogated. By bioinformatics analysis, we first found that alterations were associated with advanced PCa and exhibited mutually exclusive pattern with ERG alteration across multiple cohorts. Of the most interest, recurrent non-V600
-
Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma Neoplasia (IF 4.8) Pub Date : 2024-02-27 Shun Uchida, Satoshi Serada, Yuji Suzuki, Eiji Funajima, Kei Kitakami, Kazumasa Dobashi, Satomi Tamatani, Yuichi Sato, Takaaki Beppu, Kuniaki Ogasawara, Testuji Naka
Glioblastoma is the deadliest form of brain tumor. The presence of the blood–brain barrier (BBB) significantly hinders chemotherapy, necessitating the development of innovative treatment options for this tumor. This report presents the and efficacy of an antibody–drug conjugate (ADC) that targets glypican-1 (GPC1) in glioblastoma. The GPC1-ADC was created by conjugating a humanized anti-GPC1 antibody
-
Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection Neoplasia (IF 4.8) Pub Date : 2024-02-21 Meng-qi Jiang, Li-qiang Qian, Yu-jia Shen, Yuan-yuan Fu, Wen Feng, Zheng-ping Ding, Yu-chen Han, Xiao-long Fu
Despite promising overall survival of stage I lung adenocarcinoma (LUAD) patients, 10-25 % of them still went through recurrence after surgery. [1] While it is still disputable whether adjuvant chemotherapy is necessary for stage I patients. [2] IASLC grading system for non-mucinous LUAD shows that minor high-grade patterns are significant indicator of poor prognosis. [3] Other risk factors, such as
-
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma Neoplasia (IF 4.8) Pub Date : 2024-02-20 Liping Wang, Shuang Li, Xinran Li, Guangzheng Zhuo, Qian Zhang, Guohong Liu, Yunbao Pan
Nasopharyngeal carcinoma (NPC) and oropharyngeal carcinoma (OPC) are subtypes of head and neck cancer with different treatment effects due to the heterogeneity of tumor microenvironments. This study was to investigate the distinctive tumor microenvironments of NPC and OPC. Analyzing single-cell data from 10 cases of each subtype, we reveal significant differences in cellular composition, with NPC microenvironment
-
Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors Neoplasia (IF 4.8) Pub Date : 2024-02-16 Xiang Zhou, Rui He, Wei-Xin Hu, Saiqun Luo, Jingping Hu
Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as “Hallmarks of Cancer”, and one of their most important features is the metabolic disorders. Due to the high secretory load of the MM cells, the first-line medicine proteasome inhibitors have found
-
Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC Neoplasia (IF 4.8) Pub Date : 2024-02-13 Chao Sun, Xiaobo Ma, Fanyang Meng, Xi Chen, Xu Wang, Wenyu Sun, Yinghui Xu, Hua He, Huimao Zhang, Kewei Ma
The inconformity (IC) between pathological and imaging remissions after neoadjuvant immunotherapy in patients with NSCLC can affect the evaluation of curative effect of neoadjuvant therapy and the decision regarding the chance of surgery. Patients who achieved disease control(CR/PR/SD) after neoadjuvant chemoimmunotherapy from a clinical trial (NCT04326153) and after neoadjuvant chemotherapy during
-
A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy Neoplasia (IF 4.8) Pub Date : 2024-02-09 Casper W.F. van Eijck, Sergio Sabroso-Lasa, Gaby J. Strijk, Dana A.M. Mustafa, Amine Fellah, Bas Groot Koerkamp, Núria Malats, Casper H.J. van Eijck
Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a chemotherapy associated with high toxicity rates and variable efficacy. Therefore, it is crucial to identify patients at risk of early progression during treatment. This study aims to explore the potential of a multi-omics biomarker for predicting early PDAC progression by employing an in-depth mathematical modeling approach
-
Molecular heterogeneity in histomorphologic subtypes of lung adeno carcinoma represents a challenge for treatment decision Neoplasia (IF 4.8) Pub Date : 2024-02-03 Tobias Kolb, Sarah Müller, Peter Möller, Thomas F.E. Barth, Ralf Marienfeld
Lung cancer is the leading cause in cancer related death, with non-small cell lung cancer (NSCLC) being the most frequent subtype. The importance of NSCLC is reflected by the various targeted therapy options especially for NSCLC adenocarcinomas (lung adeno carcinoma (LUAD)) as well as a set of options for immune therapies. However, despite these therapy advances, the majority of patients do not show
-
Reciprocal regulation of lncRNA MEF and c-Myc drives colorectal cancer tumorigenesis Neoplasia (IF 4.8) Pub Date : 2024-02-01 Shuang Wu, Xiangyu Dai, Zhipu Zhu, Dianhui Fan, Su Jiang, Yi Dong, Bing Chen, Qi Xie, Zhihui Yao, Qun Li, Rick Francis Thorne, Yao Lu, Hao Gu, Wanglai Hu
More than half of all cancers demonstrate aberrant c-Myc expression, making this arguably the most important human oncogene. Deregulated long non-coding RNAs (lncRNAs) are also commonly implicated in tumorigenesis, and some limited examples have been established where lncRNAs act as biological tuners of c-Myc expression and activity. Here, we demonstrate that the lncRNA denoted c-Myc Enhancing Factor
-
High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colorectal cancer Neoplasia (IF 4.8) Pub Date : 2024-01-27 Mudasir Rashid, Rumaisa Rashid, Nikhil Gadewal, John M. Carethers, Minoru Koi, Hassan Brim, Hassan Ashktorab
The maintenance of DNA sequence integrity is critical to avoid accumulation of cancer-causing mutations. Inactivation of DNA Mismatch Repair (MMR) genes (e.g., MLH1 and MSH2) is common among many cancers, including colorectal cancer (CRC) and is the driver of classic microsatellite instability (MSI) in tumors. Somatic MSH3 alterations have been linked to a specific form of MSI called elevated microsatellite
-
FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS–STING pathway activation Neoplasia (IF 4.8) Pub Date : 2024-01-25 Yijia Wu, Yao Lin, Feiyang Shen, Rui Huang, Zhe Zhang, Min Zhou, Yan Fang, Jianfeng Shen, Xianqun Fan
F-box only protein 38 (FBXO38) is a member of the F-box family that mediates the ubiquitination and proteasome degradation of programmed death 1 (PD-1), and thus has important effects on T cell-related immunity. While its powerful role in adaptive immunity has attracted much attention, its regulatory roles in innate immune pathways remain unknown. The cyclic GMP–AMP synthase–stimulator of interferon
-
DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia Neoplasia (IF 4.8) Pub Date : 2024-01-20 Shujiao He, Yan Li, Lei Wang, Yisheng Li, Lu Xu, Diya Cai, Jingfeng Zhou, Li Yu
Background The demethylation agent decitabine (DAC) is a pivotal non-intensive alternative treatment for acute myeloid leukemia (AML). However, patient responses to DAC are highly variable, and predictive biomarkers are warranted. Herein, the DNA methylation landscape of patients treated with a DAC-based combination regimen was compared with that of patients treated with standard chemotherapy to develop
-
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial Neoplasia (IF 4.8) Pub Date : 2024-01-16 Markus Hecht, Benjamin Frey, Udo S. Gaipl, Xie Tianyu, Markus Eckstein, Anna-Jasmina Donaubauer, Gunther Klautke, Thomas Illmer, Maximilian Fleischmann, Simon Laban, Matthias G. Hautmann, Bálint Tamaskovics, Thomas B. Brunner, Ina Becker, Jian-Guo Zhou, Arndt Hartmann, Rainer Fietkau, Heinrich Iro, Michael Döllinger, Antoniu-Oreste Gostian, Andreas M. Kist
Purpose Individual prediction of treatment response is crucial for personalized treatment in multimodal approaches against head-and-neck squamous cell carcinoma (HNSCC). So far, no reliable predictive parameters for treatment schemes containing immunotherapy have been identified. This study aims to predict treatment response to induction chemo-immunotherapy based on the peripheral blood immune status
-
AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling Neoplasia (IF 4.8) Pub Date : 2024-01-18 Gaoda Ju, Tao Xing, Miaomiao Xu, Xin Zhang, Yuqing Sun, Zhuanzhuan Mu, Di Sun, Sen Miao, Li Li, Jun Liang, Yansong Lin
-
Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma Neoplasia (IF 4.8) Pub Date : 2024-01-18 Qiaoling Wang, Wuyi Liu, Huyue Zhou, Wenjing Lai, Changpeng Hu, Yue Dai, Guobing Li, Rong Zhang, Yu Zhao
Although immune checkpoint therapy has significantly improved the prognosis of patients with melanoma, urgent attention still needs to be paid to the low patient response rates and the challenges of precisely identifying patients before treatment. Therefore, it is crucial to investigate novel immunosuppressive mechanisms and targets in the tumor microenvironment in order to reverse tumor immune escape
-
RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells Neoplasia (IF 4.8) Pub Date : 2024-01-13 Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipitates secondary tumor recurrence or the spread of metastasis. In recent times, significant attention
-
Cardiac substructures dosimetric predicts cardiac toxicity and prognosis in esophageal squamous cell cancer treated by radiotherapy Neoplasia (IF 4.8) Pub Date : 2024-01-10 Zhicheng Jin, Xuefeng Sun, Chao Zhou, Haihua Yang, Suna Zhou
Purpose To look into the relationship between cardiac substructures (CS) dosimetric parameters and cardiac events (CE) or overall survival (OS) in patients undergoing radiation therapy (RT) for esophageal squamous cell carcinoma (ESCC). Methods and materials A retrospective study included 350 patients with ESCC receiving definitive chemoradiotherapy or radiotherapy (d-CRT/d-RT) or neoadjuvant chemoradiotherapy
-
Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization Neoplasia (IF 4.8) Pub Date : 2024-01-10 Jeffrey Mark Brown, Rahi Patel, Kyllie Smith-Fry, Michael Ward, Trudy Oliver, Kevin B Jones
Introduction Pleomorphic liposarcoma is a rare and aggressive subset of soft-tissue sarcomas with a high mortality burden. Local treatment largely consists of radiation therapy and wide surgical resection, but options for systemic therapy in the setting of metastatic disease are limited and largely ineffective, prompting exploration of novel therapeutic strategies and experimental models. As with other
-
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma Neoplasia (IF 4.8) Pub Date : 2024-01-06 Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan
Neuroblastoma (NB) is a predominantly pediatric cancer with greater than 90% of cases arising in children under the age of five. More than half of patients have metastases detected at diagnosis, and high-risk disease is associated with five-year survival rates of only 50–60 %. Standard therapy involves highly toxic chemotherapy, surgery, radiation, and immunotherapy, and less toxic, more specific targeted
-
Genomic profiling in GIST: Implications in clinical outcome and future challenges Neoplasia (IF 4.8) Pub Date : 2024-01-05 German Calderillo-Ruíz, Eloy Andrés Pérez-Yepez, María Alejandra García-Gámez, Oliver Millan-Catalan, Consuelo Díaz-Romero, Paul Ugalde-Silva, Rodrigo Salas-Benavides, Carlos Pérez-Plasencia, Berenice Carbajal-López
Gastrointestinal Stromal Tumors (GIST) are the most frequent mesenchymal neoplasia of the digestive tract. Genomic alterations in KIT, PDFGRA, SDH, and BRAF genes are essential in GIST oncogenesis. Therefore, the mutations in these genes have demonstrated clinical implications. Tumors with deletions in KIT-exon 11 or duplications in exon 9 are associated with a worse prognosis. In contrast, KIT-exon
-
Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis Neoplasia (IF 4.8) Pub Date : 2024-01-06 Wei Bo, Ning Yu, Xiaokai Wang, Chun Wang, Chunying Liu
Background Cisplatin resistance is one of the major obstacles in non-small cell lung cancer (NSCLC) treatment. Intriguingly, elevated lactate levels were observed in cisplatin-resistant cells, which spurred further investigation into their underlying biological mechanisms. Methods Lactate levels were measured by lactate detection kit. Cisplatin-resistance NSCLC cells were established using progressive
-
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents Neoplasia (IF 4.8) Pub Date : 2024-01-05 Anna Kopp, Hyeyoung Kwon, Colette Johnston, Steven Vance, James Legg, Laurie Galson-Holt, Greg M. Thurber
Bispecific agents are a rapidly growing class of cancer therapeutics, and immune targeted bispecific agents have the potential to expand functionality well beyond monoclonal antibody agents. Humabodies⁎ are fully human single domain antibodies that can be linked in a modular fashion to form multispecific therapeutics. However, the effect of heterogeneous delivery on the efficacy of crosslinking bispecific
-
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay Neoplasia (IF 4.8) Pub Date : 2024-01-03 Chunyu Liu, Yukun Cong, Liang Chen, Fang Lv, Lulin Cheng, Yarong Song, Yifei Xing
-
Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia Neoplasia (IF 4.8) Pub Date : 2023-12-29 Beiying Zhang, Xiaoling Deng, Ruolan You, Jingru Liu, Diyu Hou, Xiaoting Wang, Shucheng Chen, Dongliang Li, Qiang Fu, Jingdong Zhang, Huifang Huang, Xiaoli Chen
Background In addition to being secreted into the intercellular spaces by exocytosis, insulin-like growth factor binding protein 5 (IGFBP5) may also remain in the cytosol or be transported to the nucleus. Depending on the different cellular context and subcellular distribution, IGFBP5 can act as a tumor suppressor or promoter through insulin-like growth factor -dependent or -independent mechanisms
-
Advanced progress of spatial metabolomics in head and neck cancer research Neoplasia (IF 4.8) Pub Date : 2023-12-23 Huiting Zhao, Chaowen Shi, Wei Han, Guanfa Luo, Yumeng Huang, Yujuan Fu, Wen Lu, Qingang Hu, Zhengjun Shang, Xihu Yang
Head and neck cancer ranks as the sixth most prevalent malignancy, constituting 5 % of all cancer cases. Its inconspicuous onset often leads to advanced stage diagnoses, prompting the need for early detection to enhance patient prognosis. Currently, research into early diagnostic markers relies predominantly on genomics, proteomics, transcriptomics, and other methods, which, unfortunately, necessitate
-
Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases Neoplasia (IF 4.8) Pub Date : 2023-12-23 Junjie Ji, Tian Liu, Yu Yao, Wen Liu, Hao Ning, Tongyu Wang, Guiming Zhang
Objectives To explore the features, treatment, and outcomes of primary urothelial carcinoma of the prostate (PUCP) in a multicenter study. Methods The clinical and imaging features, pathological findings, treatment, and outcomes of patients diagnosed with PUCP from January 2011 to April 2022 at three institutions were collected and analyzed. The Kaplan–Meier method and log-rank test were used to assess
-
Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers Neoplasia (IF 4.8) Pub Date : 2023-12-21 Ayat Lashen, Abdulbaqi Al-Kawaz, Jennie N Jeyapalan, Shatha Alqahtani, Ahmed Shoqafi, Mashael Algethami, Michael Toss, Andrew R Green, Nigel P Mongan, Sudha Sharma, Mohammad R Akbari, Emad A Rakha, Srinivasan Madhusudan
RECQL is essential for genomic stability. Here, we evaluated RECQL in 449 pure ductal carcinomas in situ (DCIS), 152 DCIS components of mixed DCIS/invasive breast cancer (IBC) tumors, 157 IBC components of mixed DCIS/IBC and 50 normal epithelial terminal ductal lobular units (TDLUs). In 726 IBCs, CD8+, FOXP3+, IL17+, PDL1+, PD1+ T-cell infiltration (TILs) were investigated in RECQL deficient and proficient
-
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma Neoplasia (IF 4.8) Pub Date : 2023-11-30 Farrukh Afaq, Sumit Agarwal, Prachi Bajpai, Sameer Al Diffalha, Hyung-Gyoon Kim, Shajan Peter, Moh'd Khushman, Subhash C Chauhan, Priyabrata Mukherjee, Sooryanarayana Varambally, Upender Manne
Thyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression
-
Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC Neoplasia (IF 4.8) Pub Date : 2023-11-15 Andreas Kroh, Jeanette Walter, Athanassios Fragoulis, Diana Möckel, Twan Lammers, Fabian Kiessling, Julia Andruszkow, Christian Preisinger, Maren Egbert, Long Jiao, Roman M. Eickhoff, Daniel Heise, Nikolaus Berndt, Thorsten Cramer, Ulf Peter Neumann, Antje Egners, Tom Florian Ulmer
Obesity and associated nonalcoholic steatohepatitis (NASH) are on the rise globally. NASH became an important driver of hepatocellular carcinoma (HCC) in recent years. Activation of the central metabolic regulator mTOR (mechanistic target of rapamycin) is frequently observed in HCCs. However, mTOR inhibition failed to improve the outcome of HCC therapies, demonstrating the need for a better understanding
-
Evidence based on Mendelian randomization: Causal relationship between mitochondrial biological function and lung cancer and its subtypes Neoplasia (IF 4.8) Pub Date : 2023-11-16 Kangle Zhu, Jingwei Shi, Rusong Yang, Chu Zhou, Zhengcheng Liu
Objective This study aimed to investigate the causal relationship between mitochondrial biological function and lung cancer, including its subtypes, via MR. Methods SNPs significantly associated with lung cancer and its subtypes were employed as instrumental variables. MR-Egger regression, simple mode, weighted mode, simple median, and weighted median, were utilized to determine the causal relationship
-
Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy Neoplasia (IF 4.8) Pub Date : 2023-11-11 Marie Winter, Amina Nait Eldjoudi, Catherine Guette, Hubert Hondermarck, Roland P. Bourette, Quentin Fovez, William Laine, Bart Ghesquiere, Eric Adriaenssens, Jérôme Kluza, Xuefen Le Bourhis
Triple negative breast cancer (TNBC) is an aggressive malignancy for which chemotherapy remains the standard treatment. However, between 3 and 5 years after chemotherapy, about half patients will relapse and it is essential to identify vulnerabilities of cancer cells surviving neoadujuvant therapy. In this study, we established persistent TNBC cell models after treating MDA-MB-231 and SUM159-PT TNBC
-
Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system Neoplasia (IF 4.8) Pub Date : 2023-11-07 Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodi
Metastatic renal cell carcinoma (RCC) remains an incurable disease for most patients highlighting an urgent need for new treatments. However, the preclinical investigation of new therapies is limited by traditional two-dimensional (2D) cultures which do not recapitulate the properties of tumor cells within a collagen extracellular matrix (ECM), while human tumor xenografts are time-consuming, expensive
-
Acral melanoma: new insights into the immune and genomic landscape Neoplasia (IF 4.8) Pub Date : 2023-10-31 Larissa Anastacio DaCosta Carvalho, Flavia C. Aguiar, Keiran S.M. Smalley, Patricia A. Possik
Acral melanoma is a rare subtype of melanoma that arises on the non-hair bearing skin of the nail bed, palms of the hand and soles of the feet. It is unique among melanomas in not being linked to ultraviolet radiation (UVR) exposure from the sun, and, as such, its incidence is similar across populations who are of Asian, Hispanic, African and European origin. Although research into acral melanoma has
-
A sensitive and robust plasma-based DNA methylation panel for early detection of target gastrointestinal cancers Neoplasia (IF 4.8) Pub Date : 2023-11-01 Yanmiao Dai, Hui Li, Qianqian Wu, Jie Wang, Kai Wang, Sujuan Fei, Bing Pei, Lishuang Song, Guangxia Chen, Yong Ma, Chenjing Xia, Shangmin Xiong, Minxue Zheng, Ying Xue, Guodong Zhao, Hongwei Xu
Background Target gastrointestinal cancers (GICs), encompassing esophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC), originate within a single readily accessible luminal organ system and are diagnosable using endoscopy. However, endoscopy is an invasive procedure with low compliance and no plasma-based DNA methylation assay for the early detection of GICs. Methods Nine potential
-
Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations Neoplasia (IF 4.8) Pub Date : 2023-10-31 R.A. McMahon, C. D'Souza, P.J. Neeson, S. Siva
Radiation therapy is an established and effective anti-cancer treatment modality. Extensive pre-clinical experimentation has demonstrated that the pro-inflammatory properties of irradiation may be synergistic with checkpoint immunotherapy. Radiation induces double-stranded DNA breaks (dsDNA). Sensing of the dsDNA activates the cGAS/STING pathway, producing Type 1 interferons essential to recruiting
-
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center Neoplasia (IF 4.8) Pub Date : 2023-10-27 Jens von der Grün, Maiwand Ahmadsei, Isabel Breyer, Christian Britschgi, Daniel Eberli, Thomas Hermanns, Joanna Mangana, Henrik Petrowsky, Egle Ramelyte, Patrick Roth, Gabriel Schär, Isabelle Opitz, Michael Weller, Andreas Wicki, Isabell Witzel, Panagiotis Balermpas, Matthias Guckenberger
Background and purpose To analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center. Materials and methods Patient recruitment numbers in prospective clinical studies of solid malignancies were retrospectively analyzed for the years 2019 – 2021 at the Comprehensive Cancer Center
-
Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells Neoplasia (IF 4.8) Pub Date : 2023-10-17 Fridolin Grottker, Simon Gehre, Clara M. Reichardt, Azzaya Sengedorj, Tina Jost, Thorsten Rieckmann, Markus Hecht, Antoniu-Oreste Gostian, Benjamin Frey, Rainer Fietkau, Udo S. Gaipl, Michael Rückert
Purpose Human papilloma virus (HPV) positive head and neck squamous cell carcinoma (HNSCC) tumors respond significantly better to anticancer treatments. It is assumed to be due to a better response to radiotherapy (RT), and presumably to an increased immunogenicity. However, little is known how the immune phenotype of HNSCC tumor cells is modulated by standard treatment, namely by radiochemotherapy
-
Time-restricted feeding affects the fecal microbiome metabolome and its diurnal oscillations in lung cancer mice Neoplasia (IF 4.8) Pub Date : 2023-10-16 Gaofeng Fang, Shengquan Wang, Qianyao Chen, Han Luo, Xuemei Lian, Dan Shi
The homeostasis of the gut microbiota and circadian rhythm is critical to host health, and both are inextricably intertwined with lung cancer. Although time-restricted feeding (TRF) can maintain circadian synchronization and improve metabolic disorders, the effects of TRF on the fecal microbiome, metabolome and their diurnal oscillations in lung cancer have not been discussed. We performed 16S rRNA
-
Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients Neoplasia (IF 4.8) Pub Date : 2023-10-13 Hong-yu Shen, Jia-lin Xu, Zhen Zhu, Hai-ping Xu, Ming-xing Liang, Di Xu, Wen-quan Chen, Jin-hai Tang, Zheng Fang, Jian Zhang
Background Tumor antigenicity and efficiency of antigen presentation jointly influence tumor immunogenicity, which largely determines the effectiveness of immune checkpoint blockade (ICB). However, the role of altered antigen processing and presentation machinery (APM) in breast cancer (BRCA) has not been fully elucidated. Methods A series of bioinformatic analyses and machine learning strategies were
-
Targeting IL-23 for the interception of obesity-associated colorectal cancer Neoplasia (IF 4.8) Pub Date : 2023-10-07 Venkateshwar Madka, Srikanth Chiliveru, Janani Panneerselvam, Gopal Pathuri, Yuting Zhang, Nicole Stratton, Nandini Kumar, Dharambir K. Sanghera, Chinthalapally V. Rao
Inflammation and obesity are two major factors that promote Colorectal cancer (CRC). Our recent data suggests that interleukin (IL)-23, is significantly elevated in CRC tumors and correlates with patient obesity, tumor grade and survival. Thus, we hypothesize that obesity and CRC may be linked via inflammation and IL-23 may be a potential target for intervention in high-risk patients. TCGA dataset
-
Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma Neoplasia (IF 4.8) Pub Date : 2023-10-04 Musaffe Tuna, Gordon B Mills, Christopher I Amos
Acquired uniparental disomy (aUPD) is a chromosomal alteration that can lead to homozygosity of existing aberrations. We used data from The Cancer Genome Atlas SNP-based arrays to identify distinct and common aUPD profiles in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Moreover, we tested relevance of aUPD for homozygous deletion (HMD), overall survival (OS), and recurrence-free
-
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma Neoplasia (IF 4.8) Pub Date : 2023-09-29 Iyoko Katoh, Keiichi Tsukinoki, Ryu-Ichiro Hata, Shun-ichi Kurata
TP63 (p63) is strongly expressed in lower-grade carcinomas of the head and neck, skin, breast, and urothelium to maintain a well-differentiated phenotype. TP63 has two transcription start sites at exons 1 and 3′ that produce TAp63 and ΔNp63 isoforms, respectively. The major protein, ΔNp63α, epigenetically activates genes essential for epidermal/craniofacial differentiation, including ΔNp63 itself.
-
ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways Neoplasia (IF 4.8) Pub Date : 2023-09-26 Kun Wang, Jiatong Tang, Shengxian Fan, Haochen Su, Ranran Yu, Yixuan Zhang, Hao Wu, Ying Lv, Shu Zhang, Xiaoping Zou
The mortality rates of gastric cancer remain high due to limited therapeutic strategies. As a highly selective inhibitor of the BD2 domain of BET family proteins, ABBV-744 has potent chemotherapeutic activity against various human solid tumors. However, whether ABBV-744 has potential anti-tumor effects in gastric cancer remain largely unknown. In this study, we evaluated the effect of ABBV-744 on gastric
-
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study Neoplasia (IF 4.8) Pub Date : 2023-09-26 Giulia Bon, Eriseld Krasniqi, Manuela Porru, Lorenzo D'Ambrosio, Stefano Scalera, Marcello Maugeri-Saccà, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Andrea Botticelli, Daniele Santini, Maria Agnese Fabbri, Giuliana D'Auria, Claudio Pulito, Giovanni Blandino, Caterina Marchiò, Maddalena Barba, Gennaro Ciliberto, Patrizia Vici, Laura Pizzuti
The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly
-
HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma Neoplasia (IF 4.8) Pub Date : 2023-09-15 Jinxin Zhang, Lixia Liu, Yan Li, Yaling Huang, Senbo Xiao, Zihao Deng, Zhenming Zheng, Jieyou Li, Manfeng Liang, Guantai Xie, Xiao Chen, Yaotang Deng, Wenchong Tan, Hairou Su, Guibing Wu, Chunqing Cai, Xuemei Chen, Fei Zou
-
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer Neoplasia (IF 4.8) Pub Date : 2023-09-11 Inga Hoffmann, Mihnea P. Dragomir, Nanna Monjé, Carlotta Keunecke, Catarina Alisa Kunze, Simon Schallenberg, Sofya Marchenko, Wolfgang D. Schmitt, Hagen Kulbe, Jalid Sehouli, Ioana Elena Braicu, Paul Jank, Carsten Denkert, Silvia Darb-Esfahani, David Horst, Bruno V. Sinn, Christine Sers, Philip Bischoff, Eliane T. Taube
Background The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in regulating the immune system's response to tumors, but its exact role in cancer, especially in high-grade serous ovarian cancer (HGSOC), remains controversial. We aimed to investigate the prognostic impact of IDO1 expression and its correlation with tumor-infiltrating lymphocytes (TILs) in HGSOC. Methods Immunohistochemical
-
Mutational signatures and their association with survival and gene expression in urological carcinomas Neoplasia (IF 4.8) Pub Date : 2023-09-06 Peeter Karihtala, Outi Kilpivaara, Katja Porvari
Different sources of mutagenesis cause consistently identifiable patterns of mutations and mutational signatures that mirror the various carcinogenetic processes. We used publicly available data from the Cancer Genome Atlas to evaluate the associations between the activity of the mutational signatures and various survival endpoints in six types of urological cancers after adjusting for established
-
Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma Neoplasia (IF 4.8) Pub Date : 2023-08-28 Monika Sharma, Ivana Barravecchia, Brian Magnuson, Sarah F. Ferris, April Apfelbaum, Nneka E. Mbah, Jeanette Cruz, Varunkumar Krishnamoorthy, Robert Teis, McKenzie Kauss, Carl Koschmann, Costas A. Lyssiotis, Mats Ljungman, Stefanie Galban
Therapeutic resistance remains a major obstacle to preventing progression of H3K27M-altered Diffuse Midline Glioma (DMG). Resistance is driven in part by ALDH-positive cancer stem cells (CSC), with high ALDH1A3 expression observed in H3K27M-mutant DMG biopsies. We hypothesized that ALDH-mediated stemness and resistance may in part be driven by the oncohistone itself. Upon deletion of H3K27M, ALDH1A3
-
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma Neoplasia (IF 4.8) Pub Date : 2023-08-25 Xinyu Han, Mohammed O.E. Abdallah, Peter Breuer, Fabian Stahl, Yousuf Bakhit, Anna-Laura Potthoff, Barbara E.F. Pregler, Matthias Schneider, Andreas Waha, Ullrich Wüllner, Bernd O. Evert
Glioblastoma is the most common and aggressive primary tumor of the central nervous system with poor outcome. Current gold standard treatment is surgical resection followed by a combination of radio- and chemotherapy. Efficacy of temozolomide (TMZ), the primary chemotherapeutic agent, depends on the DNA methylation status of the O6-methylguanine DNA methyltransferase (MGMT), which has been identified
-
BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer Neoplasia (IF 4.8) Pub Date : 2023-08-25 Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Monica Ianniello, Marika Casillo, Nadia Petrillo, Francesco Sabbatino, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Vittorio Albino, Vincenza Granata, Francesco Izzo, Annabella Di Mauro, Massimiliano Berretta, Raffaella Ruggiero, Oreste Gualillo, Roberto Sirica, Guglielmo Nasti, Giovanni Savarese
Abstract not available
-
Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review Neoplasia (IF 4.8) Pub Date : 2023-08-19 Mariam Zeriouh, Hans Raskov, Lasse Kvich, Ismail Gögenur, Astrid Louise Bjørn Bennedsen
Background Evidence suggests that the human gut microbiota modulates the treatment response of immune checkpoint inhibitors (ICI) in cancer. Thus, finding predictive biomarkers in the fecal gut microbiota of patients who are less likely to respond to ICI would be valuable. This systematic review aimed to investigate the association between fecal gut microbiota composition and ICI-treatment response
-
Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma Neoplasia (IF 4.8) Pub Date : 2023-08-19 Alyssa Noll, Carrie Myers, Matthew C. Biery, Michael Meechan, Sophie Tahiri, Asmitha Rajendran, Michael E. Berens, Danyelle Paine, Sara Byron, Jiaming Zhang, Conrad Winter, Fiona Pakiam, Sarah E.S. Leary, Bonnie L. Cole, Evangeline R. Jackson, Matthew D. Dun, Jessica B. Foster, Myron K. Evans, Siobhan S. Pattwell, James M. Olson, Nicholas A. Vitanza
Constitutional mismatch repair deficiency (CMMRD) is a cancer predisposition syndrome associated with the development of hypermutant pediatric high-grade glioma, and confers a poor prognosis. While therapeutic histone deacetylase (HDAC) inhibition of diffuse intrinsic pontine glioma (DIPG) has been reported; here, we use a clinically relevant biopsy-derived hypermutant DIPG model (PBT-24FH) and a CRISPR-Cas9
-
KCTD1 is a new modulator of the KCASH family of Hedgehog suppressors Neoplasia (IF 4.8) Pub Date : 2023-08-17 A. Di Fiore, S. Bellardinelli, L. Pirone, R. Russo, A. Angrisani, G. Terriaca, M. Bowen, F. Bordin, Z.M. Besharat, G. Canettieri, F. Fabretti, S. Di Gaetano, L. Di Marcotullio, E. Pedone, M. Moretti, E. De Smaele
The Sonic Hedgehog (Hh) signal transduction pathway plays a critical role in many developmental processes and, when deregulated, may contribute to several cancers, including basal cell carcinoma, medulloblastoma, colorectal, prostate, and pancreatic cancer. In recent years, several Hh inhibitors have been developed, mainly acting on the Smo receptor. However, drug resistance due to Smo mutations or
-
Gut microbiota-derived short-chain fatty acids promote prostate cancer progression via inducing cancer cell autophagy and M2 macrophage polarization Neoplasia (IF 4.8) Pub Date : 2023-08-12 Yufei Liu, Quan Zhou, Fangdie Ye, Chen Yang, Haowen Jiang
-
Altered endosomal-lysosomal biogenesis in melanoma Neoplasia (IF 4.8) Pub Date : 2023-08-09 Giang T. Lam, Alexandra Sorvina, Carmela Martini, Sarita Prabhakaran, Ben S.-Y. Ung, Joanna Lazniewska, Courtney R. Moore, Andrew R. Beck, Ashley M. Hopkins, Ian R.D. Johnson, Maria C. Caruso, Shane M. Hickey, Robert D. Brooks, Louise Jackett, Litsa Karageorgos, Erwin J. Foster-Smith, Victoria Malone, Sonja Klebe, John J. O'Leary, Douglas A. Brooks, Jessica M. Logan
Cutaneous melanoma is the deadliest form of skin neoplasm and its high mortality rates could be averted by early accurate detection. While the detection of melanoma is currently reliant upon melanin visualisation, research into melanosome biogenesis, as a key driver of pathogenesis, has not yielded technology that can reliably distinguish between atypical benign, amelanotic and melanotic lesions. The